1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The persistent cognitive dysfunction in Major Depressive Disorder (MDD) represents a significant burden for patients, often not adequately addressed by standard antidepressants. Semaglutide, a GLP-1 receptor agonist (…
This study is significant because it explores a novel application of GLP-1 receptor agonists beyond their established roles in diabetes and obesity, potentially positioning them as tools for proactive health optimizat…
This study is crucial for advancing personalized medicine in Type 2 Diabetes management. By comparing Semaglutide (a GLP-1 receptor agonist that enhances insulin secretion and reduces appetite) and Dapagliflozin (an S…
This research is significant because it investigates a potential new benefit of tirzepatide beyond weight management and metabolic improvement: reducing breast cancer risk. Given the strong link between obesity and br…
Understanding how GLP-1RAs and GIP/GLP-1-dual agonists affect ocular blood flow and retinal health is critically important given their widespread use in diabetes management. If these medications demonstrate a benefici…
The introduction of resmetirom and the proven efficacy of semaglutide represent a revolutionary shift in the treatment paradigm for MASH, moving beyond solely lifestyle interventions. These drugs offer the first speci…
This study provides compelling evidence that tirzepatide not only reduces overall body weight but also dramatically improves a crucial marker of metabolic health: WHtR. Achieving a healthy WHtR is strongly associated …
This study provides important reassurance regarding the cardiovascular safety profile of tirzepatide in a high-risk population. Given tirzepatide's superior efficacy in glycemic control and weight reduction, demonstra…
The withdrawal of this trial highlights the challenges in conducting long-term comparative studies on established diabetes treatments. While this specific study yielded no results, the underlying question of how diffe…
If liraglutide proves effective in improving lung function, it would represent a significant pleiotropic benefit beyond its established role in glucose control and weight management for Type 2 Diabetes Mellitus patien…
This study is critically important because it addresses a significant unmet medical need for effective treatments for cognitive dysfunction in individuals with type 2 diabetes, a population at high risk for dementia. …
This finding is significant because it confirms that liraglutide can reach the central nervous system (CNS), providing a physiological basis for its observed central effects on appetite regulation, glucose homeostasis…
Obstructive sleep apnoea significantly impacts quality of life and carries substantial health risks, particularly in obese populations. Liraglutide, a GLP-1 analogue, is already approved for weight management and type…
This multicentre, non-interventional study provides invaluable real-world evidence on Liraglutide (Saxenda®) safety and effectiveness, which is critical for understanding its performance outside of controlled clinical…
If the collected data demonstrates positive outcomes, this study could establish liraglutide, a GLP-1 receptor agonist, as a novel neuroprotective treatment for diabetic neuropathy. This would be a significant advance…
This trial design is significant because chronic heart failure and type 2 diabetes represent a substantial global health burden, and understanding how GLP-1 (glucagon-like peptide-1) agonists impact cardiac function c…
This study highlights the potential for IDegLira to significantly improve the quality of life for very old patients with Type 2 Diabetes by streamlining their treatment. Simplifying medication regimens can enhance adh…
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
The potential findings from this study could significantly advance our understanding of Semaglutide's role in the long-term management of Type 2 Diabetes, particularly concerning the critical challenge of preventing w…
This research is crucial as it expands the understanding of GLP-1 RA efficacy beyond weight-centric applications, particularly for a patient population where weight loss might not be a primary goal or even desirable. …
This study provides crucial real-world evidence supporting the sustained renal benefits of oral semaglutide when patients transition from injectable GLP-1RAs. The convenience of an oral formulation could significantly…
This review provides a critical safety alert for clinicians prescribing semaglutide, emphasizing the need for increased vigilance regarding ocular symptoms. The findings suggest that patients on semaglutide should be …
This study provides reassuring short-term data regarding tirzepatide and calcitonin levels, suggesting that while a slight increase may occur, it generally remains within a safe range for adults with obesity. This fin…
A successful semaglutide nasal spray could offer a more convenient and potentially less invasive administration route for patients managing overweight or obesity. This novel delivery method could significantly improve…
Reducing NETosis could represent a novel therapeutic strategy for managing inflammation and progression in diabetic kidney disease and immune-mediated kidney diseases. Identifying specific drug classes like SGLT2 inhi…
This research is crucial for understanding the precise behavioral mechanisms through which GLP-1 receptor agonists promote weight loss, moving beyond self-reported data to direct observation. The identification of spe…
Oral semaglutide could offer a safer, more effective, and convenient alternative to insulin for managing post-transplant hyperglycemia, potentially mitigating risks like hypoglycemia and weight gain in a highly vulner…
This study is crucial for understanding how Semaglutide performs in a diverse patient population under typical healthcare conditions, rather than idealized trial environments. Real-world evidence complements tradition…
This perspective is crucial for understanding the potential challenges and benefits of using oral semaglutide in patients who have undergone MBS. It suggests that while the drug's mechanism of action is highly relevan…
This study provides a robust, scientifically-driven methodology for developing complex oral peptide formulations like semaglutide, potentially leading to more effective and patient-friendly treatment options. The enha…
This research provides compelling evidence that combining Liraglutide with Atorvastatin offers a synergistic therapeutic strategy for managing metabolic dysfunction, inflammation, and oxidative stress. The identificat…
This study provides compelling evidence for semaglutide's potential as a preventative pharmacological agent against life-threatening aortic events like rupture and dissection. Given the current lack of drug treatments…
This real-world study provides crucial insights into the practical application and effectiveness of semaglutide in a challenging patient population with Cardiovascular-Kidney-Metabolic Syndrome (CKM). The findings und…
This study provides compelling direct evidence that GLP-1 RAs acutely enhance the contractility of human heart muscle, independent of their systemic metabolic effects. This direct positive inotropic effect could be a …
The widespread prevalence of low-quality and misleading information about semaglutide on social media platforms poses a significant public health risk. This can lead to inappropriate self-medication, incorrect dosing,…
This review underscores the transformative potential of novel antiobesity medications in improving cardiovascular health outcomes for obese patients. The demonstrated 20% reduction in MACE by semaglutide sets a new be…
This comprehensive review underscores the critical role of the gut microbiome as a mediator of GLP-1 therapy effects on liver health, particularly in patients with Type 2 Diabetes Mellitus. Understanding these mechani…
This real-world data strongly supports the efficacy of tirzepatide in managing metabolic syndrome, especially when combined with lifestyle interventions. The substantial weight loss and significant improvements in met…
The study demonstrated significant reductions in alcohol consumption and body weight in the semaglutide group compared to placebo. > Patients treated with semaglutide experienced a 43% reduction in weekly alcohol inta…